Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Active Rotator Cuff Tendinopathy
NCT05722522Phase 3Terminated
- Sponsor
- Novartis
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of secukinumab in rotator cuff tendinopathy (RCT), sponsored by Novartis. Started Aug 2023; status: terminated.
02
Drugs
secukinumab
03
Conditions
rotator cuff tendinopathy (RCT)
Beyond the preview
Go deeper on NCT05722522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05722522.